As you might know, Dimed S.A. Distribuidora de Medicamentos (BVMF:PNVL3) last week released its latest second-quarter, and things did not turn out so great for shareholders. It wasn't a great result overall - while revenue fell marginally short of analyst estimates at R$1.5b, statutory earnings missed forecasts by an incredible 25%, coming in at just R$0.20 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following the latest results, Dimed Distribuidora de Medicamentos' six analysts are now forecasting revenues of R$6.29b in 2026. This would be a credible 6.6% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 25% to R$1.15. Before this earnings report, the analysts had been forecasting revenues of R$6.30b and earnings per share (EPS) of R$1.35 in 2026. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a real cut to EPS estimates.
See our latest analysis for Dimed Distribuidora de Medicamentos
Althoughthe analysts have revised their earnings forecasts for next year, they've also lifted the consensus price target 12% to R$19.08, suggesting the revised estimates are not indicative of a weaker long-term future for the business. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Dimed Distribuidora de Medicamentos at R$29.50 per share, while the most bearish prices it at R$15.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Dimed Distribuidora de Medicamentos'historical trends, as the 14% annualised revenue growth to the end of 2026 is roughly in line with the 12% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 9.0% annually. So although Dimed Distribuidora de Medicamentos is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Dimed Distribuidora de Medicamentos. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Dimed Distribuidora de Medicamentos analysts - going out to 2028, and you can see them free on our platform here.
You can also see whether Dimed Distribuidora de Medicamentos is carrying too much debt, and whether its balance sheet is healthy, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.